Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 2010
116th Congress(2019-2020)
CCM–CARE Act
Introduced
Introduced
Introduced in Senate on Jun 27, 2019
Overview
Text
Sponsor
Democrat
Introduced
Jun 27, 2019
Latest Action
Jun 27, 2019
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
2010
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
Tom Udall
New Mexico
Democrat
Martin Heinrich
New Mexico
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2019 or the CCM-CARE Act

This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.)

The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.

The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation.

The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

Text (1)
Introduced in Senate
June 27, 2019
Related Bills (1)
Jun 27, 2019
Introduced in House
3
Sponsorship
House Bill 3573
CCM–CARE Act
Introduced
Type
Identical Bill
Identical Bill
A bill that is word-for-word identical to another bill. Bills are characterized as identical to each other at the introduced stage only, even though a later (e.g., reported or passed) version of a bill might meet the same criteria for text similarity. Companion measures, procedurally-related measures, and legislation with text similarities are other related bill types.
Identified By
CRS
Actions (2)
06/27/2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
06/27/2019
Introduced in Senate
Public Record
Record Updated
Nov 1, 2022 1:50:51 PM
Copyright © 2024 Civic Bits LLC
Privacy Policy
Terms of Service
What's New
About